Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide by Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale Andre, Yannis Morel, Henk M. Lokhorst, Niels W.C.J. van de Donk, Paul W.H.I. Parren, Tuna Mutis

Get full text

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies by Hilma J. van der Horst, Simone C. Oostindie, Saskia. A. G. M. Cillessen, Anne T. Gelderloos, Marije B. Overdijk, Inger. S. Nijhof, Sonja Zweegman, Martine E. D. Chamuleau, Esther C. W. Breij, Tuna Mutis

Get full text

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma by Marina Zajec, Kristine A. Frerichs, Martijn M. van Duijn, Inger S. Nijhof, Claudia A.M. Stege, Hervé Avet-Loiseau, Theo M. Luider, Yolanda B. de Rijke, Joannes F.M. Jacobs, Niels W.C.J. van de Donk

Get full text

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients by Kristine A. Frerichs, Patricia W.C. Bosman, Jeroen F. van Velzen, Pieter L.A. Fraaij, Marion P.G. Koopmans, Guus F. Rimmelzwaan, Inger S. Nijhof, Andries C. Bloem, Tuna Mutis, Sonja Zweegman, Niels W.C.J. van de Donk

Get full text

P1536: SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY by Sabine Haggenburg, Tom Reuvekamp, Quincy Hofsink, Cilia R. Pothast, Romy C. Dijkland, Kayleigh van Dijk, Annoek E.C. Broers, Jaap van Doesum, Rob S. van Binnendijk, Gerco den Hartog, Michel S. Bhoekhan, Nienke J.E. Haverkate, Sandra Vogels-Nooijen, Inger S. Nijhof, Mirjam H.M. Heemskerk, Caroline E. Rutten, Abraham Goorhuis, Mette D. Hazenberg

Get full text

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients by Laurens E. Franssen, Inger S. Nijhof, Suzana Couto, Mark-David Levin, Gerard M.J. Bos, Annemiek Broijl, Saskia K. Klein, Yan Ren, Maria Wang, Harry R. Koene, Andries C. Bloem, Aart Beeker, Laura M. Faber, Ellen van der Spek, Reinier Raymakers, Roos J. Leguit, Pieter Sonneveld, Sonja Zweegman, Henk Lokhorst, Tuna Mutis, Anjan Thakurta, Xiaozhong Qian, Niels W.C.J. van de Donk

Get full text

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes by Kazimierz Groen, Febe Smits, Kazem Nasserinejad, Mark‐David Levin, Josien C. Regelink, Gert‐Jan Timmers, Esther G. M. deWaal, Matthijs Westerman, Gerjo A. Velders, Koen deHeer, Rineke B. L. Leys, Roel J. W. vanKampen, Claudia A. M. Stege, Maarten R. Seefat, Inger S. Nijhof, Ellen van derSpek, Saskia K. Klein, Niels W. C. J. van deDonk, Paula F. Ypma, Sonja Zweegman

Get full text

P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE... by Kaz Groen, Claudia Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Paula F. Ypma, Sonja Zweegman

Get full text

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context by Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Annelies Verbrugge, Danny Buitenhuis, Sonia M. Cunha, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Niels W.C.J. van de Donk, Mark-David Levin, Paula F. Ypma, Sonja Zweegman

Get full text

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort studyResearch in context by Quincy Hofsink, Sabine Haggenburg, Birgit I. Lissenberg-Witte, Annoek E.C. Broers, Jaap A. van Doesum, Rob S. van Binnendijk, Gerco den Hartog, Michel S. Bhoekhan, Nienke J.E. Haverkate, Johan van Meerloo, Judith A. Burger, Joey H. Bouhuijs, Gaby P. Smits, Dorine Wouters, Ester M.M. van Leeuwen, Hetty J. Bontkes, Neeltje A. Kootstra, Sandra Vogels-Nooijen, Nynke Rots, Josine van Beek, Mirjam H.M. Heemskerk, Kazimierz Groen, Tom van Meerten, Pim G.N.J. Mutsaers, Marit J. van Gils, Abraham Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof, Iris M.J. Kant, Thecla Graas, Belle Toussaint, Sterre de Jong, Shahan Darwesh, Sandjiv S. Mahes, Dora Kamminga, Matthijs Koelewijn, Gino Faber, Guus Beaumont, Marije D. Engel, R. Cheyenne N. Pierie, Suzanne R. Janssen, Gino Faber, Edith van Dijkman, Jarom Heijmans, Yara Y. Witte, Rogers A. Nahui Palomino, Said Z. Omar, Sonja Zweegman, Arnon P. Kater, Caya van den Vegt, Ilonka Arends-Halbesma, Emma de Pater, Margriet J. Dijkstra, Nynke Y. Rots, Esther Siteur-van Rijnstra, Dennis M. de Rooij, Rogier W. Sanders, Meliawati Poniman, Wouter Olijhoek, Jacqueline van Rijswijk, Tim Beaumont, Lusia Çetinel, Louis Schellekens, Yvonne M. den Hartogh, Jacqueline Cloos, Suzanne S. Weijers, Saïda Tonouh-Aajoud, Selime Avci, Elianne Roelandse-Koop, Willem A. Dik

Get full text